JOP: Journal of the pancreas (J Pancreas )

Journal description

Current impact factor: 0.00

Impact Factor Rankings

Additional details

5-year impact 0.00
Cited half-life 0.00
Immediacy index 0.00
Eigenfactor 0.00
Article influence 0.00
Website Journal of the Pancreas website
Other titles JOP. Journal of the Pancreas, Journal of the pancreas
ISSN 1590-8577
OCLC 46677991
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • JOP: Journal of the pancreas 01/2015; 16(1):81-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is one of the most aggressive malignant diseases in which the survival rate has not improved in the past 40 years. A fifty-one-year-old male patient with inoperable metastatic pancreatic cancer and low response to chemotherapy with gemcitabine as single therapy underwent palliative high intensity focused ultrasound (HIFU) ablation. Continuing chemotherapy with folinic acid, oxaliplatin and 5-fluorouracil (FOLFOX) was made. Tools, provided by the European Organization for Research and Treatment of Cancer (EORTC) were used to evaluate his quality of life. The Global Health Status improved from 25 to 42 out of 100 and the body mass index (BMI) increased from 14.9 to 18.1 kg/m2. Measured by the visual analog scale, the pain was reduced from 7 to 2 out of 10. Twelve months after the HIFU ablation, CT revealed decreased size of the tumor and liver lesions. FOLFOX plus interventional, physical destruction of the primary tumor by HIFU sufficiently improved the quality of life, reduced pancreatic pain and provided better survival in this case.
    JOP: Journal of the pancreas 01/2015; 16(1):66-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of pancreatic fistulae after pancreaticoduodenectomy is extremely important because it determines the patient's postoperative course. In particular, treatment of grade B cases should be conducted in a timely manner to avoid deterioration to grade C. We report the successful treatment of six cases of postoperative intractable, grade B pancreatic fistulae, in which fistula closure was achieved through the use of tissue adhesive. Six subjects presented at our hospital with grade B pancreatic fistulae after pancreaticoduodenectomy. In all cases, the drain amylase values were high immediately after the operation, and the replacement of the drain was enforced. Closure of the fistula was performed by pouring tissue adhesive into the fistula from the drain, after the fistula had been straightened. Closure of the fistula was achieved in all six cases at the first attempt. The average fistula length was 13.2 cm, the average volume of pancreatic fluid discharge just before treatment was 63.3 mL, the average amylase value in the drainage was 40,338.5 IU/L, and the subjects were discharged from hospital an average of 8.8 days after treatment. There were no recurrences after treatment. Intractable pancreatic fistulae can be effectively treated using the tissue adhesive method.
    JOP: Journal of the pancreas 01/2015; 16(1):50-2.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The major goals that must be achieved during pancreaticoduodenectomy (PD) include reduction of postoperative hemorrhage and/or operating time. We herein describe a new technique for PD examining right posterior approach PD. From January 2012 to December 2013, 116 patients underwent PD for periampullary or pancreatic disease. Of these 116 patients, 56 cases were surgically treated for pancreas head or periampullary malignancy and were studied for blood loss volume and length of operation. An interesting issue in the present study was related to operating time and intra-operative blood loss. The median blood loss volume and operating time were 349 mL (35-3,636 mL) and 276 min (188-467 min), respectively, in patients who underwent a right posterior-approach PD. The estimated operative blood loss volume and operative time are lower in right posterior approach PD, probably due to clearly detection a route of the inferior pancreaticoduodenal artery from the SMA and following early ligation of the inferior pancreaticoduodenal artery and reduced congestion of the pancreatic head.
    JOP: Journal of the pancreas 01/2015; 16(1):41-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cystic neoplasms, which are less common forms of exocrine pancreatic neoplasms, consist of mainly intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms. Mucinous cystic neoplasms, unlike IPMN, are not associated with ductal growth, are usually multilocular in nature, and have ovarian type stroma. Mucinous cystadenocarcinoma is a type of mucinous cystic neoplasm more commonly found in women. Intraductal oncocytic papillary neoplasms of the pancreas are the least common variant of IPMN. Despite this classification, intraductal oncocytic papillary neoplasms have been compared to mucinous cystic neoplasms in previous studies and the classification is still questioned. We report a rare case of an intraductal oncocytic papillary neoplasm of the pancreas occurring in a 52-year-old male with a prior history of surgically excised mucinous cystadenocarcinoma. This is the first known case of an intraductal oncocytic papillary neoplasm occurring after a prior pancreatic neoplasm. As the diagnosis of intraductal oncocytic papillary neoplasms are rare, having only a few case reports and small series on which to understand its disease process, it is imperative to discuss each case and detail possible correlations with other pancreatic cystic neoplasms as well as distinctions from its current association within IPMN.
    JOP: Journal of the pancreas 01/2015; 16(1):63-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Before the initiation of cytotoxic therapy for locally unresectable pancreatic cancer, staging laparoscopy is an important diagnostic method for both the detection of occult small lesions and the extraction of a tumor sample for advanced pathological examination using core needle biopsy (CNB) under laparoscopic ultrasonography (LUS) guidance. This study aimed to evaluate the safety and usefulness of LUS-guided CNB in pancreatic cancer. Consecutive patients with locally unresectable pancreatic cancer who underwent staging laparoscopy were retrospectively analyzed. LUS-guided CNB was performed percutaneously under a laparoscopic view. The clinical results of the LUS-guided CNB group and the non-LUS-guided CNB group were compared. Forty-eight patients who underwent staging laparoscopy by LUS-guided CNB or endoscopic ultrasound-guided fine needle aspiration were identified. LUS-guided CNB was performed in 25 patients. The mean tumor size in the LUS-guided CNB group was significantly larger than that in the non-LUS-guided CNB group. No significant difference was observed between the two groups in operating time or bleeding volume. The rates of malignancy diagnosis and histological classification subtyping were significantly higher in the LUS-guided CNB group. Histologically differentiated adenocarcinoma was identified in 15 patients using samples acquired by LUS-guided CNB. There was no uncontrollable bleeding or other complications, and a significant difference in the occurrence of peritoneal dissemination after laparoscopic examination was observed between the two groups. LUS-guided CNB enables the safe acquisition of sufficient tissue volumes for certain pathological analyses required to determine treatment strategies for locally unresectable advanced pancreatic cancer.
    JOP: Journal of the pancreas 01/2015; 16(1):45-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulinomas, which are generally smaller than 2 cm, may be difficult to detect by routine imaging modalities including abdominal ultrasonography, computed tomography, and magnetic resonance imaging. Although preoperative detection of insulinomas is essential for operative planning, it is often challenging due to their small size. While arterial stimulation and venous sampling has been used in patients with insulinomas it has been largely supplanted by early-phase thin-slice computed tomography. We report three patients with insulinomas, which were not detected by routine computed tomography scan, but were successfully imaged using early-phase thin-slice computed tomography. Enucleation was performed in all patients based on preoperative imaging. All three patients had an unremarkable postoperative course. Early-phase thin-slice computed tomography is recommended for the preoperative identification of insulinomas. This non-invasive imaging technique should be considered before performing arterial stimulation and venous sampling.
    JOP: Journal of the pancreas 01/2015; 16(1):70-3.
  • JOP: Journal of the pancreas 09/2014; 15(5):2657.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the safety and survival benefit of combined curative resection (CR) of the pancreas and major venous resection in the management of borderline resectable pancreatic adenocarcinoma.
    JOP: Journal of the pancreas 09/2014; 15(5):433-41.
  • [Show abstract] [Hide abstract]
    ABSTRACT: EUS with fine-needle aspiration and cyst fluid analysis is routinely used to evaluate pancreatic cysts; however, the clinical course of these lesions is often not well defined.
    JOP: Journal of the pancreas 05/2014; 15(5):427-32.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Surgery remains the only curative treatment for pancreatic cancer; however, majority of patients present with advanced unresectable disease upon diagnosis. Treatment of nonmetastatic, locally advanced pancreatic cancer (LAPC) continues to require multidisciplinary bimodality or trimodality approach. Neoadjuvant therapies have been investigated for LAPC given its established role in other solid cancers such as breast cancer, gastric cancer, and rectal cancer. This strategy is now moving forward to management of potentially resectable disease as well. This meeting highlight focuses on recent updates on neoadjuvant therapy for both borderline resectable disease and potentially resectable disease, Abstracts #4120, #e15189, #e15226 and #TPS4158 will be discussed.
    JOP: Journal of the pancreas 01/2014; 15(4):354-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The natural history of incidental branch-duct intraductal papillary mucinous neoplasm of the pancreas is still unknown.
    JOP: Journal of the pancreas 01/2014; 15(4):391-3.
  • JOP: Journal of the pancreas 01/2014; 15(4):411-2.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cigarette smoking is a known risk factor of pancreatic disease. Nicotine - a major cigarette tobacco component - can traffic through the circulatory system and may induce fibrosis and metastasis, hallmarks of chronic pancreatitis and pancreatic adenocarcinoma, respectively. However, at the biomolecular level, particularly in pancreatic research, the effects of nicotine remain unresolved.
    JOP: Journal of the pancreas 01/2014; 15(5):465-74.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several epidemiology studies have observed that there is a higher than expected association between diabetes mellitus (DM) and pancreatic ductal adenocarcinoma (PDAC). However, because no plausible mechanistic link exists between high glucose levels and carcinogenesis, additional risk factors are likely involved. Evaluating these epidemiologic data has been confounded by difficulty in identifying appropriate control populations and in replicating the demographics and risk found in previous studies. Furthermore, a significant subset of patients developed DM up to 2 years before the detection of cancer, suggesting that the glucose intolerance in these patients is a paraneoplastic syndrome linked to factors released from the tumor rather than typical type 1 or type 2 DM. Indeed, DM is a major co-morbidity of PDAC and is often reversed following resection of the cancer and a major part of the pancreas, while in other cases, pancreatic resection leads to DM. Finally, the DM may be associated with previous acute pancreatitis and/or subclinical chronic pancreatitis, so that the diagnosis of pancreatitis is often missed. The pancreatitis factor is important since the link between pancreatitis and pancreatic cancer is well established and a close temporal link between pancreatitis and diabetes in known. In these cases the primary epidemiology association is between DM and pancreatitis rather, and secondarily, there is a mechanistic association between pancreatitis and PDAC. To date, though, pancreatitis and pancreatogenic DM (Type 3c) has not been adequately assessed in a major epidemiology study. These observations indicate that glucose intolerance is non-specific, that PDAC can cause DM, and that pancreatitis may be an important missing link between DM and PDAC. Thus, new carefully controlled studies are needed to better understand the underlying cause of the association of PDAC with DM.
    JOP: Journal of the pancreas 01/2014; 15(5):2772.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite incredible effort on understanding and awareness of diabetes, management procedure is becoming more challenging since the complications of the disease as well as the newly discovered or yet put on market drugs that may have a suspicious association with cancer. This metabolic disorder itself does already have high prevalence of cancer such as pancreas and colon. Thyroid cancer itself is also increasing and thyroid disorders associated with diabetes is well known endocrinological problem. Rise in thyroid cancer patients in diabetics are also emphasized in meta-analyses. Obesity does seem to be another factor for thyroid cancer; however, it is also commonly associated with patients who have type 2 diabetes. GLP-1 based therapy does not only help diminish blood glucose but help satiety and lose weight as well which is a desired effect of diabetes therapy since losing weight corrects many other cardiovascular risk factors. Thyroid cancer and its connectivity to GLP-1 analogue therapy is a concern, yet not proven; although may diminish the rate of prescription by some diabetologists, although some suggest outweigh the clinical positive effect.
    JOP: Journal of the pancreas 01/2014; 15(5):2788.